<DOC>
	<DOCNO>NCT01940471</DOCNO>
	<brief_summary>The primary objective study compare efficacy , safety , tolerability tenofovir alafenamide ( TAF ) versus tenofovir disoproxil fumarate ( TDF ) treatment-naive treatment-experienced adult hepatitis B e antigen ( HBeAg ) -positive chronic hepatitis B virus ( HBV ) infection .</brief_summary>
	<brief_title>Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate Treatment Hepatitis B e Antigen-Positive Hepatitis B</brief_title>
	<detailed_description>This study GS-US-320-0110 international study plan enroll participant global country , include China . However , due review timeline difference China , full enrollment reach main study China able participate . Therefore , detail China cohort register separately ( NCT02836249 ) ClinicalTrials.gov cohorts part main study analysis .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Key Ability understand sign write informed consent form , must obtain prior initiation study procedure Adult male nonpregnant , nonlactating female Documented evidence chronic HBV infection HBeAgpositive , chronic hepatitis B following : HBeAgpositive screen Screening HBV DNA ≥ 2 x 10^4 IU/mL Screening serum alanine aminotransferase ( ALT ) level &gt; 60 U/L ( male ) &gt; 38 U/L ( female ) ≤ 10 x upper limit normal range ( ULN ) Treatmentnaive participant ( define &lt; 12 week oral antiviral treatment nucleoside nucleotide analogue ) OR treatmentexperienced participant ( defined participant meet entry criterion [ include HBV DNA serum ALT criterion ] ≥ 12 week previous treatment nucleoside nucleotide analogue ) Previous treatment interferon ( pegylated nonpegylated ) must end least 6 month prior baseline visit Adequate renal function Normal ECG Key Females breastfeed Males female reproductive potential unwilling use `` effective '' , protocol specify method ( ) contraception study Coinfection hepatitis C virus , HIV , hepatitis D virus Evidence hepatocellular carcinoma Any history , current evidence , clinical hepatic decompensation Abnormal hematological biochemical parameter , include aspartate aminotransferase ( AST ) &gt; 10 x ULN Received solid organ bone marrow transplant History malignancy within past 5 year , exception specific cancer cure surgical resection ; individual evaluation possible malignancy eligible Currently receive therapy immunomodulators ( eg , corticosteroid ) , investigational agent , nephrotoxic agent , agent capable modify renal excretion Individuals receive ongoing therapy drug use tenofovir alafenamide tenofovir disoproxil fumarate individual know hypersensitivity study drug , metabolite , formulation excipients Current alcohol substance abuse judge investigator potentially interfere participant compliance Any clinical condition prior therapy , opinion Investigator , would make participant unsuitable study unable comply dose requirement Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hepatitis</keyword>
	<keyword>Tenofovir</keyword>
	<keyword>Viread</keyword>
</DOC>